Intra-arterial administration of tenecteplase

Preclinical

Intra-arterial administration of tenecteplase is one of 37 therapeutic programs targeting Ischemic stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ischemic StrokeRecruiting

Ischemic StrokePreclinical

Recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Atorvastatin Calcium

Merck & Co.

Phase 3

1 2

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 3

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 4

Aggrastat

MMedicure

Phase 3

4 5

Zastaprazan

YYonsei University

Phase 3

1 6

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 7

Proamatine

Takeda

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

3 9

Tylenol

KKenvue Brands

Preclinical

1 10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Ischemic Stroke

NCT04201964

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK): a Prospective, Single Arm, Pilot Study

Recruiting·HHui-Sheng Chen·Preclinical·NCT04201964·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intra-arterial administration of tenecteplase. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intra-arterial administration of tenecteplase. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hui-Sheng Chen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: HHui-Sheng Chen

Intra-arterial administration of tenecteplase

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News